H. Lundbeck A/S operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares H. Lundbeck A/S with three other
pharmaceutical manufacturers in Europe:
Stada Arzneimittel AG
sales of 2.31 billion Euro [US$2.84 billion]
of which 59%
Hikma Pharmaceuticals PLC
of the United Kingdom
(£1.49 billion [US$2.07 billion]
based in France
(2.01 billion Euro [US$2.47 billion]
H. Lundbeck A/S reported sales of 17.23 billion Danish Kroner (US$2.84 billion)
December of 2017.
increase of 10.2%
versus 2016, when the company's sales were 15.63 billion Danish Kroner.
This was the third consecutive year of growth at H. Lundbeck A/S.
Sales of Northera saw an increase
that was more than double the company's growth rate: sales were up
51.2% in 2017, from
1.09 billion Danish Kroner to 1.64 billion Danish Kroner.
H. Lundbeck A/S also saw significant increases in sales in
Onfi (up 25.4% to 3.02 billion Danish Kroner)
Brintellix/trintellix (up 50.4% to 1.66 billion Danish Kroner)
Abilify Maintena (up 19.5% to 1.33 billion Danish Kroner)
Rexulti (up 51.0% to 1.25 billion Danish Kroner)
Not all segments of H. Lundbeck A/S experienced an increase in sales in 2017:
sales of Xenazine fell 33.2% to 1.05 billion Danish Kroner.
H. Lundbeck A/S also experienced decreases in sales in
Cipralex (down 5.9% to 2.37 billion Danish Kroner)